If confirmed in clinical trials, these findings may support APG-2449 as a member of a new generation of ALK multikinase inhibitors that can offset resistance in certain subpopulations of patients with NSCLC that relapses on ALK inhibitors. The gene discussed is ALK; the disease is non-small cell lung carcinoma.